Readout Newsletter: Bayer study halts, Carmot to IPO, and more

KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi 3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport




comprehensive

author：entertainment    Page View：2878
The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

advertisement

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Does good food count as health care? Study aims to find out
Next article： Peter Hotez and the public health issue of online harassment